HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palliser, D. Articles by Boes, M. Search for Related Content PubMed PubMed Citation Articles by Palliser, D. Articles by Boes, M.

Myeloid Differentiation Factor 88 Is Required for Cross-Priming In Vivo¹

Deborah Palliser^*, Hidde Ploegh^2, and Marianne Boes

^* Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; and Department of Pathology, Harvard Medical School, Boston, MA 02115

We describe a role for myeloid differentiation factor 88 (MyD88) in the induction of functional CTLs in vivo, in response to exogenously administered Ag, using a heat shock fusion protein, hsp65-P1, as a model Ag. CD8 T cells transferred into MyD88-deficient animals produce normal numbers of CD8 effector cells that have normal activation marker profiles after immunization with hsp65-P1. However, these CD8 T cells produced significantly less IFN- and showed reduced killing activity. This reduction in activation of functional CTLs appears to be unrelated to Toll-like receptor 4 function, because in vitro hsp65-P1-experienced Toll-like receptor 4-deficient dendritic cells (DCs), but not MyD88-deficient DCs, activated CD8 T cells to a similar extent to wild-type DCs. We identify a cross-presentation defect in MyD88-deficient DCs that, when treated with hsp65-P1 fusion protein, results in surface display of fewer SIYRYYGL/class I MHC complexes. Thus, MyD88 plays a role in the developmental maturation of DCs that allows them to prime CD8 T cells through cross-presentation.

This article has been cited by other articles:

				S. Zhou, E. A. Kurt-Jones, K. A. Fitzgerald, J. P. Wang, A. M. Cerny, M. Chan, and R. W. Finberg Role of MyD88 in Route-Dependent Susceptibility to Vesicular Stomatitis Virus Infection J. Immunol., April 15, 2007; 178(8): 5173 - 5181. [Abstract] [Full Text] [PDF]

				F. Takeshita, T. Tanaka, T. Matsuda, M. Tozuka, K. Kobiyama, S. Saha, K. Matsui, K. J. Ishii, C. Coban, S. Akira, et al. Toll-Like Receptor Adaptor Molecules Enhance DNA-Raised Adaptive Immune Responses against Influenza and Tumors through Activation of Innate Immunity. J. Virol., July 1, 2006; 80(13): 6218 - 6224. [Abstract] [Full Text] [PDF]

				M. Chen, C. Barnfield, T. I. Naslund, M. N. Fleeton, and P. Liljestrom MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens from Infected Cells J. Virol., March 1, 2005; 79(5): 2964 - 2972. [Abstract] [Full Text] [PDF]

				E. E. Hamilton-Williams, A. Lang, D. Benke, G. M. Davey, K.-H. Wiesmuller, and C. Kurts Cutting Edge: TLR Ligands Are Not Sufficient to Break Cross-Tolerance to Self-Antigens J. Immunol., February 1, 2005; 174(3): 1159 - 1163. [Abstract] [Full Text] [PDF]